KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Amortization of Deferred Charges (2019 - 2024)

Alnylam Pharmaceuticals (ALNY) has disclosed Amortization of Deferred Charges for 6 consecutive years, with $13.1 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Amortization of Deferred Charges rose 27.95% year-over-year to $13.1 million, compared with a TTM value of $45.2 million through Sep 2024, up 4.98%, and an annual FY2023 reading of $43.0 million, up 4.61% over the prior year.
  • Amortization of Deferred Charges was $13.1 million for Q3 2024 at Alnylam Pharmaceuticals, up from $9.7 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $13.1 million in Q3 2024 and bottomed at $9.4 million in Q1 2020.
  • Average Amortization of Deferred Charges over 5 years is $10.6 million, with a median of $10.3 million recorded in 2023.
  • The sharpest move saw Amortization of Deferred Charges dropped 12.1% in 2022, then rose 27.95% in 2024.
  • Year by year, Amortization of Deferred Charges stood at $10.5 million in 2020, then fell by 3.98% to $10.1 million in 2021, then rose by 4.94% to $10.6 million in 2022, then decreased by 0.78% to $10.5 million in 2023, then increased by 24.45% to $13.1 million in 2024.
  • Business Quant data shows Amortization of Deferred Charges for ALNY at $13.1 million in Q3 2024, $9.7 million in Q2 2024, and $12.0 million in Q1 2024.